AP Biosciences Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-447.49	-339.3	-288.54
Depreciation & Amortization	15.97	11.6	7.42
Other Amortization	0.52	0.98	1.25
Loss (Gain) From Sale of Assets	0	0	-
Stock-Based Compensation	37.4	24.74	29
Other Operating Activities	0.84	0.79	-0.89
Change in Accounts Receivable	-1.53	-2.31	-0.12
Change in Accounts Payable	4.3	14.58	-16.59
Change in Other Net Operating Assets	-9.84	-8.7	-7.51
Operating Cash Flow	-399.83	-297.62	-275.97
Capital Expenditures	-26.36	-35.03	-1.13
Sale (Purchase) of Intangibles	-0.06	-0.38	-1.31
Investment in Securities	362.28	-430.7	-0.71
Other Investing Activities	0.62	-2.56	-0
Investing Cash Flow	336.49	-468.68	-3.15
Long-Term Debt Repaid	-	-3.11	-
Net Debt Issued (Repaid)	-8.66	-3.11	-
Issuance of Common Stock	1,203	-	800
Financing Cash Flow	1,195	-3.11	800
Net Cash Flow	1,132	-769.4	520.88
Free Cash Flow	-426.18	-332.65	-277.1
Free Cash Flow Margin	-1321.37%	-1031.37%	-
Free Cash Flow Per Share	-6.54	-5.14	-5.26
Cash Interest Paid	1.93	1.13	-
Levered Free Cash Flow	-263.32	-211.61	-
Unlevered Free Cash Flow	-262.23	-210.86	-
Change in Net Working Capital	4.77	-4.41	-

Updated Aug 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.